Dr Patricia Jaaks | Postdoctoral Fellow

Jaaks, Patricia

Within the Translational Cancer Genomics group, Patricia works on large-scale combination drug screens in cancer cell lines to establish a combination drug screen analysis framework and to identify novel cancer therapies and genetic biomarkers of synergy.


  • Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer.

    Garcia-Alonso L, Iorio F, Matchan A, Fonseca N, Jaaks P et al.

    Cancer research 2018;78;3;769-780

  • The proprotein convertase furin in tumour progression.

    Jaaks P and Bernasconi M

    International journal of cancer 2017;141;4;654-663

  • The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.

    Jaaks P, Meier G, Alijaj N, Brack E, Bode P et al.

    Oncotarget 2016;7;47;76743-76755

  • Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma.

    Satheesha S, Manzella G, Bovay A, Casanova EA, Bode PK et al.

    Oncogene 2016;35;16;2020-30

  • The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion.

    Jaaks P, D'Alessandro V, Grob N, Büel S, Hajdin K et al.

    PloS one 2016;11;8;e0161396

  • The catalytic domain of inositol-1,4,5-trisphosphate 3-kinase-a contributes to ITPKA-induced modulation of F-actin.

    Ashour DJ, Pelka B, Jaaks P, Wundenberg T, Blechner C et al.

    Cytoskeleton (Hoboken, N.J.) 2015;72;2;93-100

Jaaks, Patricia
Patricia's Timeline

Postdoctoral Fellow at the Wellcome Trust Sanger Institute

Awarded PhD from University of Zurich, Switzerland PhD project: 'The proprotein convertase furin is a key regulator of paediatric sarcoma malignancy', University Children's Hospital Zurich


Graduated from Imperial College London, UK, MSc Molecular Medicine


Graduated from University of Hamburg, Germany, BSc Molecular Life Sciences